Apple shares were edging down early on Tuesday as investors digested its artificial-intelligence plans, which raised some questions among analysts. Apple stock was down 0.3% at $300.74 in premarket trading.
Apple shares were edging down early on Tuesday as investors digested its artificial-intelligence plans, which raised some questions among analysts. Apple stock was down 0.3% at $300.74 in premarket trading.
骏创科技公告,为完善海外产能布局,开拓东南亚市场,满足海外市场配套需求,公司拟以自有资金与新加坡全资子公司XCONN DEVELOPMENT PTE. LTD.共同出资300万美元在泰国设立子公司XCONN Energy Technologies (THAILAND) Co., Ltd.。拟新设公司注册资本500万元泰铢,公司持股比例为1%,新加坡子公司持股比例为99%。
骏创科技公告,为完善海外产能布局,开拓东南亚市场,满足海外市场配套需求,公司拟以自有资金与新加坡全资子公司XCONN DEVELOPMENT PTE. LTD.共同出资300万美元在泰国设立子公司XCONN Energy Technologies (THAILAND) Co., Ltd.。拟新设公司注册资本500万元泰铢,公司持股比例为1%,新加坡子公司持股比例为99%。
hapabapa Roche ( RHHBY ) said it will proceed with its planned €600M investment in a new diagnostics production facility in Penzberg, Germany, despite concerns over the German government's proposed healthcare cost-cutting measures, according to a Reuters report. The company said construction on the site, its largest single investment in Germany, remains on track for completion in 2027. "The cabine...
hapabapa Roche ( RHHBY ) said it will proceed with its planned €600M investment in a new diagnostics production facility in Penzberg, Germany, despite concerns over the German government's proposed healthcare cost-cutting measures, according to a Reuters report. The company said construction on the site, its largest single investment in Germany, remains on track for completion in 2027. "The cabinet decision is creating a new degree of uncertainty regarding investments, research, and production decisions in Germany," said Daniel Steiners, CEO of Roche Pharma AG. The decision contrasts with recent moves by Eli Lilly ( LLY ) and Boehringer Ingelheim , which have scaled back planned investments in Germany, citing planned government healthcare cost cuts. The CEO added that the government's plans risk significant economic damage with little benefit to the long-term sustainability of the healthcare system and said the parliamentary process offers a final opportunity to keep Germany on a reliable path. More on Roche Holding Roche Holding AG (RHHBY) Shareholder/Analyst Call Transcript Roche Holding AG (RHHBY) Presents at American Society of Clinical Oncology (ASCO) Annual Meeting 2026 - Slideshow Roche Holding AG (RHHBY) Analyst/Investor Day Transcript Nurix surges 43% on up to $3B cancer drug deal with Roche Zealand phase 2 data on petrelintide shows durable weight loss
当前,Coding Agents 在软件工程领域一路高歌猛进,科学家们看到此场景,也不禁寄予厚望: AI 智能体何时能以同样的速度,帮人类攻克药物设计、病毒监控与生物学建模的重重难关? 然而,一个残酷的现实是,AI 在生物学领域的发展要比编程领域慢得多…… 近日,Anthropic 发表了一篇新科学博客 ——《为生物学智能体铺平道路》(Paving the way for agents in bi...
当前,Coding Agents 在软件工程领域一路高歌猛进,科学家们看到此场景,也不禁寄予厚望: AI 智能体何时能以同样的速度,帮人类攻克药物设计、病毒监控与生物学建模的重重难关? 然而,一个残酷的现实是,AI 在生物学领域的发展要比编程领域慢得多…… 近日,Anthropic 发表了一篇新科学博客 ——《为生物学智能体铺平道路》(Paving the way for agents in biology),文章指出: 阻碍生物学 AI Agent 爆发的瓶颈,根本不在于大模型底座的推理能力不够强,而在于人类现有的生物学数据基础设施实在是太落后了。 因此,如果希望 AI Agent 真正参与生物学研究,生物数据基础设施必须变得更适合 Agent 使用。 这篇文章由 Laura Luebbert 撰写,她是一位生物学家与机器学习研究员。 有意思的是,Laura Luebbert 透露,这篇博客是在 Karpathy 官宣加入 Anthropic 之前一周就完成的,因为文中部分内容涉及 Karpathy ,还担心 Anthropic 会不会觉得这篇「Karpathy 味」太重。没想到的是,就在她把初稿发给 Anthropic 的同一天,他们就官宣了…… 下面,我们就来详细看一下,这篇文章是如何分析的? 现有生物数据基础设施,对 Agent 来说太难走了 作者用了一个很有意思的类比, 让 AI Agent 去操作生物数据基础设施,有点像开车穿过一座在汽车出现前就建好的老城: 这座城市也许很美,规划也有其用心之处,但里面到处是狭窄、曲折的街道,现代车辆难以顺畅通行。对应到生物数据领域,就是各种特有的文件格式、分散的数据库,以及一次性的检索脚本。 当然,你也可以试着给这座城市补上交通标志、停车场,甚至偶尔拓宽几条道路,但它最基本的布局仍然难以通行,原因在于它原本就是为另一种交通方式设计的。 相比之下,软件基础设施几乎天然就适合「汽车」,也就是 Agent 使用:铺好的道路、清晰的车道、标准化信号,以及支持从起点到终点快速通行的系统,也就是版本控制、文档清晰的 API 和包管理器。 因此,Coding Agent 的发展速度明显快于生物学 Agent。 软件领域通常具备结构化的数字工作流和可靠接口,而计算生物学中用于数据检索和验证的基础设施,往往脆弱、异构,并且高度依赖具体流...
The history of megacap initial public offerings shows that the stocks usually slump in the first year of trading. But upcoming listings from SpaceX , Anthropic and OpenAI are big enough and systemically important enough to the market that those analogies may not apply. All which poses a crucial timing question for investors: When is the right moment to buy shares in one of the upcoming mega-tech I...
The history of megacap initial public offerings shows that the stocks usually slump in the first year of trading. But upcoming listings from SpaceX , Anthropic and OpenAI are big enough and systemically important enough to the market that those analogies may not apply. All which poses a crucial timing question for investors: When is the right moment to buy shares in one of the upcoming mega-tech IPOs? “These behemoth IPOs will rapidly take up both the market share of benchmarks and the mindshare of retail investors,” said Max Gokhman , senior vice president at Franklin Templeton Investment Solutions. Looking at 30 major technology IPOs over the past 15 years, Truist Wealth found that they averaged a maximum decline of 55% in the first year of trading. Forward returns skewed negative at the six-month mark as well, according to Truist calculations. There are numerous possible reasons for the weakness, including low public share floats and added selling pressure from the expiration of lockups preventing early investors from selling right away. The difference, however, is the IPOs that are coming aren’t your normal megacap deals. SpaceX, which is officially known as Space Exploration Technologies Corp., is seeking $75 billion in what’s set to be the largest IPO of all time , valuing the company at about $1.8 trillion. Anthropic has held private funding rounds that value it at $965 billion, and OpenAI is worth $852 billion based on its own fundraising. All three jumbo-sized offerings are expected to result in market values of more than $1 trillion or at least very close to it. There are currently only 11 companies in the S&P 500 Index with market capitalizations above $1 trillion. “I have never been asked more about an IPO than SpaceX from our retail clients and advisers,” said Matt Stucky , chief portfolio manager of equities at Northwestern Mutual Wealth Management Co. “That’s interesting, but at the same time it’s also a little concerning just from a risk management p...
The devil’s in the details. | Image: Cath Virginia / The Verge, Donut Labs Donut Lab's solid-state battery claims have been thoroughly debunked by Ryan Inis Hughes on his popular Ziroth YouTube channel . According to Hughes, Donut Lab has engaged in deliberate, calculated deception by claiming to have a solid-state battery ready for mass production . In reality, it's nothing more than a standard l...
The devil’s in the details. | Image: Cath Virginia / The Verge, Donut Labs Donut Lab's solid-state battery claims have been thoroughly debunked by Ryan Inis Hughes on his popular Ziroth YouTube channel . According to Hughes, Donut Lab has engaged in deliberate, calculated deception by claiming to have a solid-state battery ready for mass production . In reality, it's nothing more than a standard lithium-ion design. Hughes' investigation got an assist from whistleblower Lauri Peltola , the former Chief Commercial Officer (CCO) of Nordic Nano Group - the company supposedly partnered with Donut Lab to manufacture the batteries. Hughes says he also turned to "over 20 independent battery experts," including Julian Zahnow … Read the full story at The Verge.
China is moving to leverage data as a core strategic asset, aiming to build industry-specific data sets to power its next-generation artificial intelligence models, as developers worldwide grapple with a looming data drought. On Monday, the country’s data authority unveiled a sweeping nationwide plan to boost the supply of high-quality AI training data, underscoring Beijing’s resolve to secure a l...
China is moving to leverage data as a core strategic asset, aiming to build industry-specific data sets to power its next-generation artificial intelligence models, as developers worldwide grapple with a looming data drought. On Monday, the country’s data authority unveiled a sweeping nationwide plan to boost the supply of high-quality AI training data, underscoring Beijing’s resolve to secure a leading position in the global AI competition. The draft plan, published online by the National Data...
pingingz/iStock via Getty Images I'm a bull on Rapid7, Inc. ( RPD ), after assessing the promising takeaways from its CEO appointment and its inorganic transaction. RPD's 3Q24 outperformance and its appeal as a buyout candidate were detailed in my earlier November 11, 2024 article . A Changing Of The Guard Last Monday, the firm issued an announcement revealing that " Wael Mohamed will assume the r...
pingingz/iStock via Getty Images I'm a bull on Rapid7, Inc. ( RPD ), after assessing the promising takeaways from its CEO appointment and its inorganic transaction. RPD's 3Q24 outperformance and its appeal as a buyout candidate were detailed in my earlier November 11, 2024 article . A Changing Of The Guard Last Monday, the firm issued an announcement revealing that " Wael Mohamed will assume the role of Chief Executive Officer." I've a favorable opinion of this latest move. During the William Blair 46th Growth Stock Conference on June 2, RPD indicated that the new leader is tasked to "operationalize key [product] releases that are coming up over the next nine months." The company has upheld its existing full-year forecasts too. RPD's FY26 outlook points to a "Free Cash Flow" or "FCF" of $0.13B (mid-point). That's the same as the $130.1M it registered last year. Also, management highlighted at Blair's early-Jun event that the "guidance implies our margins improve through the year." This aligns with the sell-side's sequential EBIT-to-sales expansion estimates of +0.3ppts, +3.2ppts, and +0.6ppts for 2Q26, 3Q26, and 4Q26, respectively. My take is that RPD is confident about delivering stable FCF and profitability accretion because of the incoming CEO's background and actions. Wael knows the group well, having been on the board for 14 months before taking the helm. Having worked in the digital security space for over three decades, he is a seasoned industry insider. One of Wael's accomplishments as a director was the recruitment of a new Chief Commercial Officer to reorganize RPD's "Go-To-Market/GTM" division in late-2025. This has already begun to pay off. The Blair conference disclosures highlighted that there was "a nice uptick in year-over-year productivity per rep" in 1Q2026. The CFO stressed during the Jun 2 investor event that Rapid7's executive suite is now "routinely talking about balanced growth." This sends me a clear message that both top-line and margins wil...